Avantor stock
AVTRNYSEAvantor, Inc., HealthcareISIN US05352A1007
53Score 53 out of 100, Neutral
Price and trend
76 / 100
Price history
+37% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 39% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 31).
The price is 9.0% below its 52-week high. Largest decline in 7 years: 83% (September 2021 to March 2026).
Chart figures for advanced users
- SMA 50$15.67
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.34
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)31
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.41
- The lowest closing price of the last twelve months.
- Resistance$17.29
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Avantor, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $10.66B, is number 16 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $6.55B (down 3.4% year on year) and a loss of $530.2M.
- For fiscal 2026, analysts expect on average revenue of $6.67B (up 1.8%) and adjusted earnings per share of $0.82 (down 10.2%).
Show more
- MEQIRI Score 53 out of 100 (Neutral): rank 355 of 714 in Healthcare, median 53.
- The P/E is 31.8 (Medical (Instruments & Supplies) median 34.8, own median of recent years 34.1).
- Our model puts fair value at $17.19, with the price 8% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 130% of earnings over the last 12 months.Fundamentals 64
Weaknesses
- Margin fallingOperating margin −3.8%, average of the prior years 13.2% (to 2024).Profitability 38
- Turned to a lossEarnings per share from $0.09 in 2020 to −$0.78.Growth 49
- DilutionShare count up 18% since 2020.Capital allocation 19
Its standout strengths are momentum and technical analysis, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 51 to 53.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $12.28 and expensive above $28.64 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $17.15 (cash-flow model) and $17.22 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly below both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $15.74, at 7.8% it would be $19.36.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 0.9% on the twelve months before. Revenue has grown strongly since 2015, at around 26% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 33%, operating −4%, net −8%. Last 12 months: net 5%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 10 Feb 2027in 90 days
- Last reported
- 28 Oct 2026EPS reported $0.22 (expected $0.21)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.82+0.5%
- Revenue
- $6.67B+1.2%
- Earnings per share
- $0.89+1.0%
- Revenue
- $6.86B+1.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −2.6%Avantor raised its full year 2026 guidance: organic revenue growth now 0.75% to 1.25% versus lower before, adjusted EPS raised to $0.81 to $0.83, and free cash flow guidance increased to $520 million to $550 million.
“For the full year 2026, we have raised our organic revenue growth outlook to a range of 0.75 to 1.25%, which reflects our Q3 revenue outperformance as well as modestly higher growth assumptions for Q4. Our guidance implies Q4 organic revenue growth of 2.5 to 4.5%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Lucier Gregory TPurchase
8 May 2026, Board
- Shares
- 10,000
- Price
- $8.32
- Value
- $83,200
- Dingemans SimonPurchase
1 May 2026, Board
- Shares
- 25,000
- Price
- $8.14
- Value
- $203,500
- Mehra Sanjeev KPurchase
10 Mar 2026, Board
- Shares
- 125,000
- Price
- $8.01
- Value
- $1M
Show 4 more
- Lucier Gregory TPurchase
19 Feb 2026, Board
- Shares
- 50,000
- Price
- $9.16
- Value
- $458,000
- Summe Gregory LPurchase
12 Feb 2026, Board
- Shares
- 100,000
- Price
- $9.40
- Value
- $940,000
- Mehra Sanjeev KPurchase
5 Dec 2025, Board
- Shares
- 350,000
- Price
- $11.09
- Value
- $3.88M
- Ligner EmmanuelPurchase
17 Nov 2025, President and CEO
- Shares
- 87,500
- Price
- $11.35
- Value
- $993,125
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Avantor
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 53
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- SolventumSOLV $15.06B61
- Baxter InternationalBAX $13.63B47
- Cooper CompaniesCOO $11.97B61
- RepligenRGEN $11.03B51
- AptarGroupATR $9.07B65
- Bausch + LombBLCO $7.62B50
- Asahi Intecc7747.T $6.34B83
- Gan & Lee Pharmaceuticals.603087.SS $6.21B56
ETFs that hold Avantor
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.32% | 0.30% | €944.34M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.31% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.21% | 0.43% | €2.48B |
Show 5 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.15% | 0.35% | €434.1M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.10% | 0.35% | €8.19B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.03% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.02% | 0.17% | €8.6B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.01% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.